Skip to Main Content
Diseases of the Endocrine System, Phase II

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

What is the purpose of this trial?

The primary objective of the study is to determine the proportion of patients with elevated triglycerides (TG), without familial chylomicronemia syndrome (FCS) due to loss of function (LoF) mutations in lipoprotein lipase (LPL), and a history of hypertriglyceridemia (HTG)-associated acute pancreatitis (AP) who experience a recurrent episode of AP after treatment with evinacumab versus placebo.

  • Trial with
    Regeneron Pharmaceuticals, Inc.
  • Ages
    18 years - 80 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Thiruvengadam Muniraj

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    07/23/2024
  • Study HIC
    #2000031006